Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

被引：0
|
作者：
Seike, M. [1 ]
Inoue, A. [2 ]
Sugawara, S. [3 ]
Morita, S. [4 ]
Hosomi, Y. [5 ]
Ikeda, S. [6 ]
Watanabe, K. [7 ]
Takahashi, K. [8 ]
Fujita, Y. [9 ]
Harada, T. [10 ]
Minato, K. [11 ]
Takamura, K. [12 ]
Kobayashi, K. [13 ]
Nukiwa, T. [14 ]
机构：
[1] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[2] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan
[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[6] Cardiovasc & Resp Ctr, Div Resp Med, Yokohama, Kanagawa, Japan
[7] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[8] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[9] Asahikawa Med Ctr, Resp Med, Asahikawa, Hokkaido, Japan
[10] JCHO Hokkaido Hosp, Dept Pulm Med, Sapporo, Hokkaido, Japan
[11] Gunma Prefectural Canc Ctr, Dept Pulm Med, Ota, Japan
[12] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[13] Saitama Med Univ, Int Med Ctr, Dept Pulm Med, Saitama, Japan
[14] Tohoku Univ, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1382PD
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [1] Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
    Nakamura, Atsushi
    Inoue, Akira
    Morita, Satoshi
    Hosomi, Yukio
    Kato, Terufumi
    Fukuhara, Tatsuro
    Gemma, Akihiko
    Takahashi, Kazuhisa
    Fujita, Yuka
    Harada, Toshiyuki
    Minato, Koichi
    Takamura, Kei
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [3] Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation
    Inoue, Akira
    Hosomi, Yukio
    Maemondo, Makoto
    Sugawara, Shunichi
    Kato, Terufumi
    Takahashi, Kazuhlsa
    Fujita, Yuka
    Gamma, Aklhlko
    Harada, Toshiyuki
    Oizumi, Satoshi
    Minato, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group
    Kobayashi, K.
    Inoue, A.
    Maemondo, M.
    Sugawara, S.
    Isobe, H.
    Oizumi, S.
    Saijo, Y.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3587 - +
  • [7] A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Saijo, Y.
    Genma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (03): : 6 - 6
  • [8] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
    Uchibori, Ken
    Satouchi, Miyako
    Sueoka-Aragane, Naoko
    Urata, Yoshiko
    Sato, Akemi
    Imamura, Fumio
    Inoue, Takako
    Tachihara, Motoko
    Kobayashi, Kazuyuki
    Katakami, Nobuyuki
    Kokan, Chiyuki
    Hirashima, Tomonori
    Iwanaga, Kentaro
    Mori, Masahide
    Aoe, Keisuke
    Morita, Satoshi
    Negoro, Shunichi
    [J]. LUNG CANCER, 2018, 124 : 65 - 70
  • [9] Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Saijo, Y.
    Yoshizawa, H.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group
    Minegishi, Y.
    Inoue, A.
    Kobayashi, K.
    Gemma, A.
    Maemondo, M.
    Oizumi, S.
    Saijo, Y.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (04): : 25 - 25
12345